Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Common Equity (2019 - 2026)

C4 Therapeutics has reported Common Equity over the past 8 years, most recently at $234.2 million for Q1 2026.

  • For Q1 2026, Common Equity rose 20.04% year-over-year to $234.2 million; the TTM value through Mar 2026 reached $234.2 million, up 20.04%, while the annual FY2025 figure was $256.6 million, 18.8% up from the prior year.
  • Common Equity for Q1 2026 was $234.2 million at C4 Therapeutics, down from $256.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $364.5 million in Q1 2022 and troughed at $154.4 million in Q3 2025.
  • A 5-year average of $250.2 million and a median of $246.1 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: skyrocketed 38.23% in 2022 and later plummeted 36.37% in 2025.
  • Year by year, Common Equity stood at $289.2 million in 2022, then fell by 14.91% to $246.1 million in 2023, then fell by 12.24% to $216.0 million in 2024, then increased by 18.8% to $256.6 million in 2025, then fell by 8.71% to $234.2 million in 2026.
  • Business Quant data shows Common Equity for CCCC at $234.2 million in Q1 2026, $256.6 million in Q4 2025, and $154.4 million in Q3 2025.